Trueblood Wealth Management LLC bought a new position in shares of Perspective Therapeutics, Inc. (NYSE:CATX – Free Report) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 16,236 shares of the company’s stock, valued at approximately $217,000.
Several other hedge funds have also recently bought and sold shares of the business. Janus Henderson Group PLC acquired a new position in shares of Perspective Therapeutics during the first quarter worth about $15,511,000. Affinity Asset Advisors LLC acquired a new position in Perspective Therapeutics during the 1st quarter worth approximately $6,069,000. Vanguard Group Inc. boosted its holdings in Perspective Therapeutics by 34.6% in the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after acquiring an additional 4,566,356 shares during the period. Nicholson Wealth Management Group LLC acquired a new stake in Perspective Therapeutics in the third quarter valued at approximately $21,390,000. Finally, Ally Bridge Group NY LLC purchased a new stake in shares of Perspective Therapeutics during the second quarter valued at approximately $3,951,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.
Perspective Therapeutics Stock Down 3.0 %
Shares of NYSE CATX opened at $11.53 on Friday. The firm has a 50 day moving average price of $13.76. Perspective Therapeutics, Inc. has a twelve month low of $2.20 and a twelve month high of $19.05.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the stock. Royal Bank of Canada lowered their price target on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a report on Friday, August 16th. Wedbush reaffirmed an “outperform” rating and set a $20.00 target price on shares of Perspective Therapeutics in a research report on Thursday. UBS Group initiated coverage on Perspective Therapeutics in a report on Thursday. They issued a “buy” rating and a $20.00 price target for the company. Bank of America began coverage on Perspective Therapeutics in a report on Thursday, July 25th. They set a “buy” rating and a $24.00 price objective on the stock. Finally, Truist Financial started coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price on the stock. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $20.63.
View Our Latest Stock Report on CATX
About Perspective Therapeutics
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Read More
- Five stocks we like better than Perspective Therapeutics
- ETF Screener: Uses and Step-by-Step Guide
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Are Some of the Best Large-Cap Stocks to Buy?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- MarketBeat Week in Review – 10/21- 10/25
Want to see what other hedge funds are holding CATX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perspective Therapeutics, Inc. (NYSE:CATX – Free Report).
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.